Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

NCT00874419 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

165

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: erlotinib
DRUG: gemcitabine/carboplatin

Sponsor

Tongji University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]